The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy analysis of CDK4/6 inhibitors (CDKi) + endocrine therapy (ET) treatment in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (aBC): Biomarker analysis including chemoendocrine score (CES) by CDKi type in SOLTI-1801_CDK-PREDICT study.
 
Pablo Tolosa Ortega
Consulting or Advisory Role - Adamed; AstraZeneca; Daiichi Sankyo; Novartis; Seagen
Speakers' Bureau - AstraZeneca; Daiichi-Sankyo; Lilly; Novartis; Pfizer; Seagen
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Pfizer
 
Tomás Pascual
Consulting or Advisory Role - Novartis; Roche/Genentech
Speakers' Bureau - AstraZeneca; Novartis; Pfizer; Veracyte
 
Cristina Hernando
Consulting or Advisory Role - Novartis; Pfizer
Travel, Accommodations, Expenses - AstraZeneca/Daiichi Sankyo; Novartis; Pfizer; Roche
 
Sonia Servitja
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Pharmaceutical; Gilead Sciences; Novartis
Speakers' Bureau - Novartis
 
María Fernández-Abad
Honoraria - DAIICHI SANKYO ESPANA SAU; Eisai; Lilly; Novartis
Consulting or Advisory Role - Lilly; Seagen
 
Fara Brasó-Maristany
No Relationships to Disclose
 
Javier David Benitez Fuentes
No Relationships to Disclose
 
Laura Lema
No Relationships to Disclose
 
Lucia Parrilla Rubio
No Relationships to Disclose
 
Yolanda Ruano
No Relationships to Disclose
 
Ana María Roncero
No Relationships to Disclose
 
Rodrigo Sanchez-Bayona
Honoraria - AstraZeneca; GlaxoSmithKline; Lilly; Novartis; Seagen
Consulting or Advisory Role - GlaxoSmithKline; Lilly; Novartis
Speakers' Bureau - AstraZeneca; Novartis
Expert Testimony - AstraZeneca; Novartis
Travel, Accommodations, Expenses - AstraZeneca; Pfizer
 
Manuel Alva Bianchi
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - Novartis
 
Guillermo Villacampa
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline
Speakers' Bureau - MSD Oncology; Pierre Fabre
 
María Ángeles Cobos-Fernández
No Relationships to Disclose
 
María del Rocío Moreno
No Relationships to Disclose
 
Jordi Canes
No Relationships to Disclose
 
Fernando Salvador
No Relationships to Disclose
 
Aleix Prat
Employment - Reveal Genomics
Stock and Other Ownership Interests - Reveal Genomics
Honoraria - Amgen; Daiichi Sankyo; Guardant Health; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; NanoString Technologies (Inst); Novartis; Oncolytics; Pfizer; Puma Biotechnology; Roche
Research Funding - Incyte (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - HER2DX filing; METHODS FOR BREAST CANCER TREATMENT AND PREDICTION OF THERAPEUTIC RESPONSE (US 63/023785); PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; WO/2018/096191. Chemoendocrine score (CES) Based on PAM50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics; Peptomyc
 
Eva M Ciruelos
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; MSD Oncology; Novartis; Novartis; Pfizer; Roche; Seagen
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Lilly; Novartis; Roche
Travel, Accommodations, Expenses - Pfizer; Roche